Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: substance P analogues - New Amsterdam Sciences

Drug Profile

Research programme: substance P analogues - New Amsterdam Sciences

Alternative Names: Neurokinin-1 receptor agonists - New Amsterdam Sciences

Latest Information Update: 25 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New Amsterdam Sciences
  • Developer National Institutes of Health (USA); New Amsterdam Sciences
  • Class Peptides
  • Mechanism of Action Immunostimulants; Neurokinin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Idiopathic pulmonary fibrosis; Influenza virus infections
  • Discontinued Acute radiation syndrome; Diabetic foot ulcer

Most Recent Events

  • 25 Apr 2023 Discontinued - Preclinical for Acute radiation syndrome in USA (PO) before April 2023 (New Amsterdam Sciences pipeline, April 2023)
  • 25 Apr 2023 Discontinued - Preclinical for Diabetic foot ulcer in USA (unspecified route) before April 2023 (New Amsterdam Sciences pipeline, April 2023)
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top